Hostname: page-component-7479d7b7d-qlrfm Total loading time: 0 Render date: 2024-07-09T10:30:05.467Z Has data issue: false hasContentIssue false
  • English
  • Français

P0052 - Efficacy and tolerability of Escitalopram in patients with moderate to severe depression with or without comorbid anxiety

Published online by Cambridge University Press:  16 April 2020

S. Stamouli ,
A. Vidalis ,
I. Stathakis ,
H. Bastas  and
S. Koulis
S. Stamouli
Affiliation:
Psychiatric Clinic, Eginition University Hospital of Athens, Athens, Greece
A. Vidalis
Affiliation:
Psychiatric Clinic, Ippokrateion General Hospital of Thessaloniki, Thessaloniki, Greece
I. Stathakis
Affiliation:
Psychiatric Clinic, Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece
H. Bastas
Affiliation:
Center of Mental Health, Heraklion, Greece
S. Koulis
Affiliation:
Center of Mental Health, Patra, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Purpose:

Evaluate the efficacy and tolerability of escitalopram in outpatients with moderate to severe depression in naturalistic settings.

Methods:

Open label 24 weeks study. Efficacy assessment was based on MADRS, HAM-D, HAM-A, CGI-S and VAS scales. Tolerability was evaluated by spontaneously reported adverse events and treatment discontinuation rates. Statistical analysis was based on an intent-to-treat dataset (ITT - at least one valid post-baseline MADRS measurement, prediction of previous visits using multiple linear regression) and observed cases (OC -MADRS measurements at all 6 visits).

Results:

A total of 112 patients between 18 and 65 years old were enrolled. 52 patients (46.4%) suffered from moderate depression (22£ MADRS<30) and 60 (53.6%) from severe depression(MADRS 330). Patients had a significant improvement in their symptoms at the end of the study, as measured by a mean change in MADRS total score of 21.2 ± 7.1 (ITT, multiple linear regression). Change from baseline was bigger in regards to severity of illness (p<0.001). In addition, 89.1% of patients were evaluated as responders (at least 50% decrease in MADRS total score) and 68.2% were evaluated as remitters (MADRS£12) at the end of the study (ITT, multiple linear regression). The results were similar in the OC analysis as well. In total 33 patients (29.5%) withdrew from the study for any reason, -6 of them (5.4%) due to adverse events and 1 (0.9) due to lack of efficacy.

Conclusion:

Escitalopram displayed very good efficacy and tolerability in a group of depressed outpatients suffering from moderate to severe illness.

Type
Poster Session II: Antidepressants
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S207
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.